Loading…
The Department of Biotechnology has identified six thematic verticals under the BioE3 Policy for establishing Biomanufacturing Hubs and Biofoundries.
Five priority sectors have been identified for Bio-AI hubs: Ayurveda, agriculture innovations, genome diagnostics, synthetic biology and biomolecular design.
The policy provides financial assistance of up to 70 per cent of project cost, with the remaining 30 per cent contributed by the private sector, to draw in start-ups, MSMEs and industry.
Over 600 beneficiaries have used the biofoundry and biomanufacturing facilities so far, and private investment commitments of Rs 602.09 crore have been mobilised.
Implementation is expected to generate about 1,500 direct and indirect jobs over five years in Tier-II and Tier-III cities, supporting the target of a USD 300 billion bioeconomy by 2030.
Enable scale-up and validation of bio-based technologies developed by start-ups, innovators and industry.
Key: One of the three 'Bioenablers' under BioE3, established after multi-tier evaluation of proposals received through nationwide calls.
Provide shared automated facilities for designing, building and testing biological systems, so innovators need not build their own infrastructure.
Key: Together with the hubs, has served over 600 beneficiaries so far.
Apply artificial intelligence to biological research and product development.
Key: Five priority sectors identified - Ayurveda, agriculture innovations, genome diagnostics, synthetic biology and biomolecular design.
Ensure transparent, competitive allocation of support.
Key: Letters of Intent invited through national calls, screened by a Screening Committee on eligibility, then technical evaluation by a Selection Committee, financial evaluation by a Financial Evaluation Committee covering co-funding, equity and royalty sharing, and final recommendation by an Apex Committee.
Biomanufacturing uses living systems - engineered microbes, cells, enzymes - as the production line, so that chemicals, plastics, proteins, fuels and medicines are grown rather than synthesised from petroleum. A biofoundry is the shared, heavily automated facility where that engineering happens: it runs the design-build-test-learn cycle at scale, assembling and screening thousands of genetic constructs far faster than a conventional laboratory could. The reason the State funds these rather than leaving them to firms is a classic infrastructure problem. A biofoundry is expensive, its capacity is lumpy, and no single start-up can justify building one, yet without access to one a start-up cannot move a promising organism from bench to product. Providing the facility as shared infrastructure - along with up to 70 per cent of project cost - lowers the entry barrier for exactly the small firms that would otherwise be locked out. That is also why the employment target is aimed at Tier-II and Tier-III cities: the hubs are placed where the research base exists but the private capital does not.
Simple Analogy: A biofoundry is to biotechnology what a shared industrial kitchen is to food start-ups - the equipment is too costly to own alone, but with access to it a small team can go from recipe to product.
GS Paper 3 > Science and Technology: Biotechnology, Developments and Applications; Economy: Industrial Growth
General Awareness > Science and Technology, Government Policies
General Awareness > Government Schemes and Economy
With reference to the recent developments in science, which one of the following statements is not correct?
Answer: Functional chromosomes can be created by joining segments of DNA taken from cells of different species.
Biotechnology policy and the bioeconomy target have featured in UPSC Prelims and Mains since the policy's approval in 2024.
Biotechnology for Economy, Environment and Employment - the policy approved by the Union Cabinet in August 2024 for high-performance biomanufacturing.
A shared, automated facility running the design-build-test-learn cycle for engineered biological systems.
Alternative protein products made through fermentation, plant sources or cell culture rather than conventional animal agriculture; one of the six BioE3 verticals.
Targeted biological medicines including monoclonal antibodies, mRNA therapeutics and cell and gene therapy.
Biologically derived crop inputs such as biofertilisers, biopesticides and biostimulants, under the climate-resilient agriculture vertical.
The share of economic activity derived from biological resources and biotechnology; India's target is USD 300 billion by 2030.